Gufic Biosciences working capital

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY22 and earlierAlpha Plus

234.56×	234.56×	203.27×	179.71×	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
118.32×	118.32×	143.48×	121.13×
155.03×	155.03×	158.30×	138.80×
197.85×	197.85×	188.45×	162.04×
3.45×	3.32×	3.46×	3.53×
0.75×	0.75×	0.72×	0.83×
0.70×	0.70×	1.76×	−0.09×
0.30×	0.30×	0.91×	−0.05×

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

GUFICBIO₹423.75

Gufic Biosciences Limited

· Pharma & Health

₹ CrorePeersRPGLIFE UNICHEMLAB GUJTHEM ORCHPHARMA SMSPHARMA INDSWFTLAB FDC IOLCPMcap ₹4,249 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Inventory Days (DIO)	—	179.71	203.27	234.56	234.56
Receivable Days (DSO)	—	121.13	143.48	118.32	118.32
Payable Days (DPO)	—	138.80	158.30	155.03	155.03
Cash Conversion Cycle (days)	—	162.04	188.45	197.85	197.85
Working Capital Turnover	—	3.53	3.46	3.32	3.45
Asset Turnover	—	0.83	0.72	0.75	0.75
Cash Conversion (CFO/Net Income)	—	-0.09	1.76	0.70	0.70
CFO/EBITDA	—	-0.05	0.91	0.30	0.30

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.